Recombinant RSV (Felvizumab Biosimilar) anticorps

N° du produit ABIN5668206

Détail du produit anti-RSV (Felvizumab Biosimilar) anticorps

Antigène: RSV (Felvizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Respiratory Syncytial Virus (RSV)

Hôte: Human

Clonalité: Monoclonal

Conjugué: Cet anticorp RSV (Felvizumab Biosimilar) est non-conjugé

Application: ELISA, Functional Studies (Func)

Specificité: This antibody is specific for the conserved fusion (F) protein of RSV.

Attributs du produit:

OriginalSpeciesName: Human

OriginalFormat: IgG1

Purification: Purified antibody.

Pureté: > 98 % as determined by SDS-PAGE

niveau d'endotoxine: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogène: This antibody was prepared by the humanization of an F protein-specific murine MAb, RSV19. More specifically, molecular techniques were used to insert the complementarity determining regions from murine RSV19 into a human IgG1 heavy and k light chain-variable domain framework.

Clone: RSHZ19

Isotype: IgG1 kappa

Information d'application

Indications d'application: Though shown to be safe and well-tolerated (Everitt, 1996) and protective against RSV infection in BALB/c mice and cotton rats (Wyde, 1995), this antibody did not demonstrate efficacy in a Phase 3 study (Reichert, 2008). In in vitro studies, palivizumab, another humanized Mab specific for the F protein of RSV, was 4 to 5-fold more potent than felvizumab in neutralising RSV (Scott, 1999).

Restrictions: For Research Use only

Stockage

Buffer: PBS with 0.02 % Proclin 300.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Détails sur RSV (Felvizumab Biosimilar)

Antigène: RSV (Felvizumab Biosimilar)

Abstract: RSV (Felvizumab Biosimilar) Produits

Classe de substances: Biosimilar

Sujet: SB 209763, respiratory syncytial virus